OmniAb Inc. has announced the launch of its new OmniUltra™ platform, marking an expansion of its technology portfolio. OmniUltra is the industry's first transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, broadening therapeutic opportunities beyond conventional antibodies. The platform, introduced at the 2025 Antibody Engineering & Therapeutics Conference, expands OmniAb's reach into new markets and applications and reinforces its leadership in next-generation antibody discovery technologies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OmniAb Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251215018419) on December 15, 2025, and is solely responsible for the information contained therein.